Meeting
2015 Gastrointestinal Cancers Symposium
Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites.
Authors
Ozge Gumusay
Gazi University Hospital, Ankara, Turkey
Ozge Gumusay , Mustafa Benekli , Ozgur Ekinci , Meltem Baykara , Ahmet Ozet , Ugur Coskun , Aytug Uner , Ayse Dursun , Ecine Yesim Atak , Suleyman Buyukberber
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Prevention, Diagnosis, and Screening
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 25)
DOI
10.1200/jco.2015.33.3_suppl.25
Abstract #
25
Poster Bd #
A25
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinicopathological features of HER2-low expressed advanced gastric cancers.
First Author: Izuma Nakayama
Poster
2019 Gastrointestinal Cancers Symposium
Comparison of HER2 expression by immunohistochemistry and HER2 copy number by digital PCR in tumor tissue during treatment with trastuzumab in the prospective cohort of metastatic HER2-positive gastric cancer patients.
First Author: Naoki Takahashi
Poster
2017 Gastrointestinal Cancers Symposium
Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: Results of GASTric cancer HER2 reassessment study 3 (GASTHER3).
First Author: Seyoung Seo
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The expanded indications of HER2-targeted therapies by monitoring of circulating tumor cells.
First Author: Yasuaki Kimura